ArticleMethods and protocols2025
AgentMol: Multi-Model AI System for Automatic Drug-Target Identification and Molecule Development.
Article in Methods and protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Drug discovery remains a time-consuming and costly process, necessitating innovative computational approaches to accelerate early stage target identification and compound development. We introduce AgentMol, a modular multimodel AI system that integrates large language models, chemical language modeling, and deep learning-based affinity prediction to automate the discovery pipeline. AgentMol begins with disease-related queries processed through a Retrieval-Augmented Generation system using the Large Language Model to identify protein targets. Protein sequences are then used to condition a GPT-2-based chemical language model, which generates corresponding small-molecule candidates in SMILES format. Finally, a regression convolutional neural network (RCNN) predicts the drug-target interaction by estimating binding affinities (pKi). Models were trained and validated on 470,560 ligand-protein pairs from the BindingDB database. The chemical language model achieved high validity (1.00), uniqueness (0.96), and diversity (0.89), whereas the RCNN model demonstrated robust predictive performance with R
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.